Latest news and press releases about Oramed Pharmaceuticals Inc. (ORMP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
Price
| Price | $4.62 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 1.09 |
| Price / Book | 0.60 |
| EV / EBITDA | 1.26 |
| Dividend Yield | 5.41% |
Profitability
| Return on Equity | 72.96% |
| Return on Invested Capital | -3.21% |
| Return on Assets | 47.31% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · IMA · KLRS
Explore sector: Healthcare · Biotechnology
More sections of ORMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks